Enhancing Attention in Adults With Compulsive Hoarding

NCT01100268 | Completed Phase 2 Results DMC

• 1 other identifier: 6133
• Study Type: interventional
• Target: 4
• Locations: 1 country
• Sites: 2

Brief Summary

Available data suggest that compulsive hoarders have cognitive deficits, particularly with sustaining attention that might contribute their hoarding symptoms.

Conditions

Hoarding Disorder

Keywords

Hoarding

Outcome Measures

Primary Outcomes (1)

• Number of Patients Who Met and Exceeded Response Criteria of Attention Deficit Hyperactivity Disorder Symptom Scale

  Patients given Attention Deficit Hyperactivity Disorder Symptom Scale (ADHDSS), a measure of the features of Attention Deficit Hyperactivity Disorder including inattention, hyperactivity, and impulsivity. This scale has shown excellent reliability in prior studies of individuals with HD. For the ADHDSS the minimum units are 0 and Maximum units on the total scale are 54 (adult). The higher the number on the ADHDSS, the more severe the symptoms. Response was defined as at least a 30% reduction on the ADHDSS.

  4 weeks

Secondary Outcomes (1)

• Number of Patients Who Met Response Criteria for the Saving Inventory-Revised.

  4 weeks

Study Arms (1)

Methylphenidate ER

EXPERIMENTAL

Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.

Drug: Methylphenidate ER

Interventions

Methylphenidate ER DRUG

Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.

Also known as: Concerta

Methylphenidate ER

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Clinically significant compulsive hoarding (Proposed DSM-V criteria) that is principal (i.e. currently most severe and needing of treatment) and has been present for at least one year.
• At least moderate attentional difficulties.
• Able to provide consent.
• Patients can be on or off of serotonin reuptake inhibitors (SRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) but dose must be stable for 12 weeks prior to study.

You may not qualify if:

• Currently taking any psychotropic medications other than SRIs or SNRIs.
• Presence of psychotic symptoms or lifetime history of schizophrenia, bipolar disorder or other psychotic disorder.
• Current major depression is permitted if clearly secondary in importance to the hoarding.
• Judged clinically to be at risk of suicide (suicidal ideation, severe depression or other factors)
• Any cardiovascular abnormality that increases the risk of participation, including significant history of cardiovascular disease or family history of sudden death.
• Any medical or neurological disorder that increases the risk of participation or that is a medical contraindication for taking methylphenidate (e.g. glaucoma or Tourette's syndrome).
• Current use of any drug that is contraindicated with methylphenidate (e.g. monoamine oxidase inhibitors).
• Female patients who are pregnant or nursing.
• Current or previous treatment with methylphenidate or CBT for hoarding.
• Current ETOH/drug abuse or dependence disorder of dependency in the past 6 months.
• Individuals with mild cognitive impairments, dementia, or significant intellectual deficits.

Sponsors & Collaborators

• New York State Psychiatric Institute: lead
• Hartford Hospital: collaborator

Study Sites (2)

Institute of Living

Hartford, Connecticut, 06106, United States

Location

New York State Psychiatric Insitute

New York, New York, 10032, United States

Location

Related Publications (1)

• Rodriguez CI, Bender J Jr, Morrison S, Mehendru R, Tolin D, Simpson HB. Does extended release methylphenidate help adults with hoarding disorder?: a case series. J Clin Psychopharmacol. 2013 Jun;33(3):444-7. doi: 10.1097/JCP.0b013e318290115e. No abstract available.

  PMID: 23609401 BACKGROUND

Related Links

• Columbia University Obsessive-Compulsive Disorder Clinic

MeSH Terms

Conditions

Hoarding Disorder; Hoarding

Interventions

Methylphenidate

Condition Hierarchy (Ancestors)

Obsessive-Compulsive Disorder; Anxiety Disorders; Mental Disorders; Behavior

Intervention Hierarchy (Ancestors)

Phenylacetates; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Dr. Carolyn Rodriguez
• Organization: Columbia University Department of Psychiatry

cr2163@columbia.edu

(646) 774-8061

Study Officials

• Carolyn I. Rodriguez, M.D., Ph.D.

  Columbia-NYSPI-RFMH

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 5, 2010
• First Posted: April 8, 2010
• Study Start: April 1, 2010
• Primary Completion: April 1, 2011
• Study Completion: April 1, 2011
• Last Updated: September 18, 2014
• Results First Posted: August 15, 2013

Record last verified: 2014-08

Locations

US (2)